RT Journal Article
SR Electronic
T1 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.02.21258076
DO 10.1101/2021.06.02.21258076
A1 Dhar, Mahesh S
A1 Marwal, Robin
A1 Radhakrishnan, VS
A1 Ponnusamy, Kalaiarasan
A1 Jolly, Bani
A1 Bhoyar, Rahul C.
A1 Sardana, Viren
A1 Naushin, Salwa
A1 Rophina, Mercy
A1 Mellan, Thomas A
A1 Mishra, Swapnil
A1 Whittaker, Charles
A1 Fatihi, Saman
A1 Datta, Meena
A1 Singh, Priyanka
A1 Sharma, Uma
A1 Ujjainiya, Rajat
A1 Batheja, Nitin
A1 Divakar, Mohit Kumar
A1 Singh, Manoj K
A1 Imran, Mohamed
A1 Senthivel, Vigneshwar
A1 Maurya, Ranjeet
A1 Jha, Neha
A1 Mehta, Priyanka
A1 Vivekanand, A
A1 Sharma, Pooja
A1 Arvinden, VR
A1 Chaudhary, Urmila
A1 Soni, Namita
A1 Thukral, Lipi
A1 Flaxman, Seth
A1 Bhatt, Samir
A1 Pandey, Rajesh
A1 Dash, Debasis
A1 Faruq, Mohammed
A1 Lall, Hemlata
A1 Gogia, Hema
A1 Madan, Preeti
A1 Kulkarni, Sanket
A1 Chauhan, Himanshu
A1 Sengupta, Shantanu
A1 Kabra, Sandhya
A1 ,
A1 Gupta, Ravindra K.
A1 Singh, Sujeet K
A1 Agrawal, Anurag
A1 Rakshit, Partha
YR 2021
UL http://medrxiv.org/content/early/2021/08/20/2021.06.02.21258076.abstract
AB Delhi, the national capital of India, has experienced multiple SARS-CoV-2 outbreaks in 2020 and reached a population seropositivity of over 50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant B.1.617.2 (Delta) replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and partial reduction of immunity elicited by prior infection (median estimates; ×1.5-fold, 20% reduction). Seropositivity of an employee and family cohort increased from 42% to 86% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.One-Sentence Summary Delhi experienced an overwhelming surge of COVID-19 cases and fatalities peaking in May 2021 as the highly transmissible and immune evasive Delta variant replaced the Alpha variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/